title: [Effect of compound qizhu granule on cellular immunity of chronic hepatitis B patients].
abstract: OBJECTIVE
  To explore the effect of compound qizhu granule (CQG) on cellular immunity of chronic hepatitis B (CHB) patients.
  
  
  METHODS
  Totally 103 CHB patients treated with lamivudin (LAM) for 6 months, who had partial virological response (HBeAg positive) were randomly assigned to two groups, 50 in the treatment group and 53 in the control group. All patients took LAM 100 mg (once a day) plus ADV 10 mg (once a day). Patients in the treatment group additionally took CQG, one dose per day. After one-year treatment hepatitis B virus (HBV) DNA negative rates, HBeAg seroconversion, levels of HBV specific cytotoxic T lymphocyte (CTL), non-specific CTL and natural killing (NK) cells were compared between the two groups.
  
  
  RESULTS
  After 1-year treatment, HBV DNA negative rate of the treatment group was 88: 0% in 44 cases, slightly higher than that of the control group (41 cases, 77.4%), but with no statistical difference (P >0.05). HBeAg seroconversion of the treatment group was 32.0% in 16 cases, higher than that of the control group (8 cases, 15.1%), with statistical difference (P <0.05). Levels of HBV specific CTL (0.79%±0. 07%), non-specific CTL (19.4%±1.8%) and NK cells (14. 1%± 1.5%) of the treatment group were higher than those of the control group (0.58% ± 0.08%, 17.5% ± 1.7%, and 11.1%±1.5%, respectively; allP <0.01).
  
  
  CONCLUSIONS
  Treating CHB patients with partial virological response by ADV plus CQG could improve specific and non-specific cellular immunity, thereby elevating HBeAg seroconversion rate.
authors.forename: Yin-fang
authors.initials: YF
authors.lastname: Zhu
authors.forename: Xi-bing
authors.initials: XB
authors.lastname: Gu
authors.forename: Xiao-ye
authors.initials: XY
authors.lastname: Guo
authors.forename: Zhi-han
authors.initials: ZH
authors.lastname: Yan
authors.forename: Yun-chuan
authors.initials: YC
authors.lastname: Pu
authors.forename: Kang-wan
authors.initials: KW
authors.lastname: Tu
authors.forename: Zhong
authors.initials: Z
authors.lastname: Hua
authors.forename: Hao
authors.initials: H
authors.lastname: Pei
mesh_terms: D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D006513:Hepatitis B e Antigens / Q000276:immunology; D006515:Hepatitis B virus / Q000235:genetics; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects
chemical_list: D004365:Drugs, Chinese Herbal; D006513:Hepatitis B e Antigens